Checkpoint Inhibitor PK and ADA Clinical Assays for Pembrolizumab: CMIC Inc.
CMIC Inc. offers validated, ready-to-use Pembrolizumab PK and ADA assays for sponsors conducting oncology clinical trials. Developed in-house to ensure faster study timelines and cost-efficiency, these assays are fully validated in accordance with ICH-M10 and FDA immunogenicity guidance, and utilize the MSD electrochemiluminescence platform. Trust CMIC’s 35+ years of bioanalytical expertise and GLP compliance to streamline your biomarker and immunogenicity testing needs.
Key Highlights:
-
GLP-compliant Pembrolizumab PK & ADA assays validated in human serum
-
Designed for biosimilar and co-administered drug studies
-
Specific to oncology trials with matrix selectivity and drug interference testing
-
High sensitivity, robust stability, and rapid turnaround with in-study support
-
Backed by CMIC’s global bioanalytical infrastructure and scientific leadership
Download the PDF brochure to learn more about our clinical assay capabilities.
